-
EASL Highlights | EASL-EASD-EASO Jointly Release Clinical Practice Guidelines for Metabolic Associated Fatty Liver Disease
On June 7, 2024, at 5:30 PM in Milan, Italy, the European Association for the Study of the Liver (EASL), the European Association for the Study of Diabetes (EASD), and the European Association for the Study of Obesity (EASO) jointly released the latest Clinical Practice Guidelines for the management of Metabolic Associated Fatty Liver Disease…
-
ASCO Hot Review | Professor Yu Chen: Safety and Efficacy of CXCR1/2 Inhibitor SX-682 in Combination with Pembrolizumab in Metastatic Melanoma Patients
As immunotherapy continues to make breakthroughs in treating malignant tumors, it has significantly improved the survival rates of melanoma patients. However, there remains an urgent need to develop new drugs and optimize immunotherapy strategies for patients resistant or intolerant to current treatments. At the ongoing 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, several…
-
ASCO China Voice | Professor Min Yan: Utidelone Combined with Bevacizumab is Safe and Effective for Treating Brain Metastases in HER2-Negative Breast
Brain metastasis from breast cancer has a high incidence, second only to lung cancer . Previous studies have shown that patients with brain metastases have poorer survival compared to those without brain metastases, with HER2-negative breast cancer brain metastasis patients having an even worse prognosis . Due to the blood-brain barrier (BBB), many drug treatments…
-
ASCO Hot Review | Professor Yu Chen: Safety and Efficacy of CXCR1/2 Inhibitor SX-682 in Combination with Pembrolizumab in Metastatic Melanoma Patients with Disease Progression on Anti-PD-1 Therapy
As immunotherapy continues to make breakthroughs in treating malignant tumors, it has significantly improved the survival rates of melanoma patients. However, there remains an urgent need to develop new drugs and optimize immunotherapy strategies for patients resistant or intolerant to current treatments. At the ongoing 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, several…
-
ASCO Highlights | Professor Peng Yuan: Patient-Reported Outcomes from the TROPION-Breast01 Study on Dato-DXd for HR+/HER2- Breast Cancer
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago, USA, from May 31 to June 4. At this year’s ASCO conference, the TROPION-Breast01 study (Oral Abstract Session: Abstract No. 1006) once again attracted attention and discussion. Professor Sonia Pernas from the Institut Català d’Oncologia presented a special report on June…
-
EASL China Voice | Dr. Rui Huang’s Team: Muscle Gain and Fat Loss Help Reduce Mortality Risk in Cirrhosis Patients
From June 5-8, 2024, the European Association for the Study of the Liver (EASL) Annual Meeting took place in the beautiful city of Milan, Italy. Over 7,000 liver disease experts from around the world attended this top-tier academic event. The conference covered a range of diseases including viral hepatitis, metabolic associated fatty liver disease, cirrhosis,…
-
DiabetesLiver Score for Predicting Advanced Liver Fibrosis and Adverse Liver Events in Type 2 Diabetes Patients
On June 5, 2024, the European Association for the Study of the Liver (EASL) Annual Meeting commenced in Milan, Italy, bringing together experts and scholars from the global hepatology field. The conference aimed to share the latest developments and trends in liver disease research, providing valuable references for future research and clinical practice. On the…
-
EASL China Voice | Professor Guohong Han: Upgraded Prognostic Prediction for HCC Patients Undergoing TACE – “6-and-12 Model 2.0”
Transarterial chemoembolization (TACE) is the recommended treatment for intermediate-stage hepatocellular carcinoma (HCC) patients and a viable option for early-stage HCC patients who cannot undergo curative treatments. However, the prognosis for TACE varies significantly among individuals, with objective response rates ranging from 40% to 80% and overall survival times from 13 to 48 months. Given the…
Connecting Medical Expertise through Media